@Menta
There are other places outside the US.
But your source of Misinformation is based in the garbage that they spew out there isn't it?
And you don't have the competence to find stuff for yourself do you?
Let alone evaluate it?
A List of SOME of the studies
aa-Henry 2018 {published data only}
Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O,
Gasparini R, et al. One or two doses of live varicella viruscontaining vaccines: eAicacy, persistence of immune responses,
and safety six years aMer administration in healthy children
during their second year of life. Vaccine 2018;36(3):381-7.
aa-Povey 2019 {published data only}
Povey M, Henry O, Riise Bergsaker MA, Chlibek R, Esposito S,
Flodmark CE, et al. Protection against varicella with two doses
of combined measles-mumps-rubella-varicella vaccine or one
dose of monovalent varicella vaccine: 10-year follow-up of a
phase 3 multicentre, observer-blind, randomised, controlled
trial. Lancet Infectious Diseases 2019;19(3):287-97.
aa-Prymula 2014 {published data only}
Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S,
Snegova N, et al. Protection against varicella with two
doses of combined measles-mumps-rubella-varicella
vaccine versus one dose of monovalent varicella vaccine: a
multicentre, observer-blind, randomised, controlled trial.
Lancet 2014;383(9925):1313-24. [PUBMED: 24485548]
ab-Bloom 1975 {published data only}
Bloom JL, SchiA GM, Graubarth H, Lipp RW Jr, Jackson JE,
Osborn RL, et al. Evaluation of a trivalent measles,
mumps, rubella vaccine in children. Journal of Pediatrics
1975;87(1):85-7.
ab-Ceyhan 2001 {published data only}
Ceyhan M, Kanra G, Erdem G, Kanra B. Immunogenicity and
eAicacy of one dose measles-mumps-rubella (MMR) vaccine
at twelve months of age as compared to monovalent measles
vaccination at nine months followed by MMR revaccination at
fiMeen months of age. Vaccine 2001;19(31):4473-8.
ab-Edees 1991 {published data only}
Edees S, Pullan CR, Hull D. A randomised single blind trial
of a combined mumps measles rubella vaccine to evaluate
serological response and reactions in the UK population. Public
Health 1991;105(2):91-7.
ab-Freeman 1993 {published data only}
Freeman TR, Stewart MA, Turner L. Illness aMer measlesmumps-rubella vaccination. Canadian Medical Association
Journal 1993;149(11):1669-74.
ab-Lerman 1981 {published data only}
Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic
evaluation of measles, mumps, and rubella (HPV-77E-5 and
RA 27/3) virus vaccines, singly and in combination. Pediatrics
1981;68(1):18-22.
ab-Peltola 1986 {published data only}
Peltola H, Heinonen OP. Frequency of true adverse reactions
to measles-mumps-rubella vaccine. A double-blind placebocontrolled trial in twins. Lancet 1986;1(8487):939-42.
ab-Schwarz 1975 {published data only}
Ehrenkranz NJ, Ventura AK, Medler EM, Jackson JE, Kenny MT.
Clinical evaluation of a new measles-mumps-rubella combined
live virus vaccine in the Dominican Republic. Bulletin of the
World Health Organization 1975;52(1):81-5.
Ramos-Alvarez M, Bessudo L, Kenny MT, Jackson JE,
Schwarz AJ. Simultaneous administration at diAerent dosages
of attenuated live virus vaccines against measles, mumps and
rubella [Administracion simultanea en diferentes dosificaciones
de las vacunas de virus vivos atenuados contra el sarampion,
parotiditis y rubeola]. Boletín Médico del Hospital Infantil de
México 1976;33(4):875-86.
* Schwarz AJ, Jackson JE, Ehrenkranz NJ, Ventura A, SchiA GM,
Walters VW. Clinical evaluation of a new measles-mumpsrubella trivalent vaccine. American Journal of Diseases of
Children 1975;129(12):1408-12.
Walters VW, Miller SA, Jackson JE, Kenny MT. A field with
a liver measles-mumps-rubella vaccine. Clinical Pediatrics
1975;14(10):928-33.
ba-Andrade 2018 {published data only}
Andrade AL, da Silva Vieira MA, Minamisava R, Toscano CM,
de Lima Souza MB, Fiaccadori F, et al. Single-dose varicella
vaccine eAectiveness in Brazil: a case-control study. Vaccine
2018;36(4):479-83. [PUBMED: 29249544]
ba-Castilla 2009 {published data only}
Castilla J, Fernandez Alonso M, Garcia Cenoz M, Martinez
Artola V, Inigo Pestana M, Rodrigo I, et al. Resurgence of mumps
in the vaccine era. Factors involved in an outbreak in Navarre,
Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal.
Factores implicados en un brote en Navarra, 2006-2007].
Medicina Clínica 2009;133(20):777-82.
* Castilla J, Garcia Cenoz M, Arriazu M, Fernandez-Alonso M,
Martinez-Artola V, Etxeberria J, et al. EAectiveness of Jeryl
Lynn-containing vaccine in Spanish children. Vaccine
2009;27(15):2089-93.
ba-Cenoz 2013 {published data only}
Cenoz MG, Martinez-Artola V, Guevara M, Ezpeleta C,
Barricarte A, Castilla J. EAectiveness of one and two doses
of varicella vaccine in preventing laboratory-confirmed
cases in children in Navarre, Spain. Human Vaccines and
Immunotherapeutics 2013;9(5):1172-6. [DOI: 10.4161/hv.23451]
ba-Defay 2013 {published data only}
Defay F, De Serres G, Skowronski DM, Boulianne N, Ouakki M,
Landry M, et al. Measles in children vaccinated with 2 doses
of MMR. Pediatrics 2013;132(5):e1126-33. [DOI: 10.1542/
peds.2012-3975]
ba-Fu 2013 {published data only}
Fu C, Xu J, Cai Y, He Q, Zhang C, Chen J, et al. EAectiveness
of one dose of mumps vaccine against clinically diagnoses
mumps in Guangzhou, China, 2006-2012. Human Vaccines and
Immunotherapeutics 2013;9(12):2524-8. [DOI: 10.4161/hv.26113]
